Condensed Consolidated Statements of Convertible Preferred Stock and Stockholders' Deficit (Unaudited) - USD ($) $ in Thousands		Preferred Stock [Member] Founders Convertible Preferred Stock [Member]	Preferred Stock [Member] Series A-1 Convertible Preferred Stock [Member]	Preferred Stock [Member] Series A-2 Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	AOCI Attributable to Parent [Member]	Retained Earnings [Member]	Noncontrolling Interest [Member]	Total
Balance at Dec. 31, 2022	[1]	$ 1,354	$ 3,871	$ 4,376		$ 19,930	$ (14)	$ (70,356)		$ (50,440)
Balance, shares at Dec. 31, 2022	[1]	432,982	179,665	105,928	858,373
Stock-based compensation						1,434				1,434
Foreign currency translation adjustments							2			2
Net loss								(6,462)		(6,462)
Issuance of common stock per short term loan agreement dated 1/3/23						45				45
Issuance of common stock per short term loan agreement dated 1/3/23, shares	[1]				540
Issuance of common stock per short term loan agreement dated 1/4/23						23				23
Issuance of common stock per short term loan agreement dated 1/4/23, shares	[1]				270
Issuance of common stock per short term loan agreements (various)						119				119
Issuance of common stock per short term loan agreements (various), shares	[1]				2,165
Exercise of common stock options						181				181
Exercise of common stock options, shares					15,609
Balance at Mar. 31, 2023	[1]	1,354	3,871	4,376		21,732	(12)	(76,818)		(55,098)
Balance, shares at Mar. 31, 2023	[1]				876,957
Balance at Dec. 31, 2022	[1]	$ 1,354	$ 3,871	$ 4,376		19,930	(14)	(70,356)		(50,440)
Balance, shares at Dec. 31, 2022	[1]	432,982	179,665	105,928	858,373
Issuance of common stock in lieu of cash for SEPA commitment fee
Net loss										$ (20,987)
Exercise of common stock options, shares										19,773
Balance at Sep. 30, 2023						90,253	(4)	(91,343)		$ (1,094)
Balance, shares at Sep. 30, 2023					3,543,643
Balance at Mar. 31, 2023	[1]	$ 1,354	$ 3,871	$ 4,376		21,732	(12)	(76,818)		(55,098)
Balance, shares at Mar. 31, 2023	[1]				876,957
Series B financing costs						2,680				2,680
Stock-based compensation						1,080				1,080
Foreign currency translation adjustments							(5)			(5)
Net loss								(12,501)		(12,501)
Issuance of common stock per short term loan agreements (various)						85				85
Issuance of common stock per short term loan agreements (various), shares	[1]				1,307
Exercise of common stock options						50				50
Exercise of common stock options, shares					2,082
Balance at Jun. 30, 2023	[1]	$ 1,354	$ 3,871	$ 4,376		25,627	(17)	(89,319)		(63,709)
Balance, shares at Jun. 30, 2023	[1]	432,982	179,665	105,928	880,346
Stock-based compensation						1,109				1,109
Foreign currency translation adjustments							13			13
Net loss								(2,024)		(2,024)
Exercise of common stock options						50				50
Exercise of common stock options, shares					2,082
Conversion of preferred stock into common stock		$ (1,354)	$ (3,871)	$ (4,376)		9,601				9,601
Conversion of preferred stock into common stock , shares		(432,982)	(179,665)	(105,928)	718,574
Issuance of common stock in lieu of cash per settlement agreement						11				11
Issuance of common stock in lieu of cash per settlement agreement					155
Issuance of common stock for Calidi debt settlement in connection with Merger						2,234				2,234
Issuance of common stock for Calidi debt settlement in connection with merger , shares					38,782
Issuance of common stock for deferred compensation settlement in connection with Merger						333				333
Issuance of common stock for deferred compensation settlement in connection with merger ,shares					4,683
Issuance of common stock to Calidi stockholders as result of Merger						56,101				56,101
Issuance of common stock to Calidi stockholders as result of Merger, shares					1,668,339
Issuance of common stock to Non-Redemption and PIPE Agreement Investor in connection with Merger						2,763				2,763
Issuance of common stock to Non-Redemption and PIPE Agreement Investor in connection with merger ,shares					130,682
Issuance of common stock under Forward Purchase Agreement in connection with Merger						4,520				4,520
Issuance of common stock under Forward Purchase Agreement in connection with merger, shares					100,000
Issuance of warrants for deferred compensation settlement in connection with Merger						705				705
Assumed liabilities from Merger						(6,808)				(6,808)
Assumed warrant liability from Merger						(3,389)				(3,389)
Deferred financing fees in connection with Merger						(2,604)				(2,604)
Balance at Sep. 30, 2023						90,253	(4)	(91,343)		(1,094)
Balance, shares at Sep. 30, 2023					3,543,643
Balance at Dec. 31, 2023					$ 1	91,383	(47)	(99,572)		(8,235)
Balance, shares at Dec. 31, 2023					3,552,223,000
Issuance of common stock in lieu of cash for services						29				29
Issuance of common stock in lieu of cash for services, shares					5,000
Issuance of common stock in lieu of cash for SEPA commitment fee						81				81
Issuance of common stock in lieu of cash for SEPA commitment fee, shares					13,875
Issuance of common stock to Calidi stockholders as result of Merger
Issuance of common stock to Calidi stockholders as result of Merger, shares					1,581
Issuance of common stock for legal settlement						158				158
Series B financing costs						(327)				(327)
Stock-based compensation						888				888
Foreign currency translation adjustments							58			58
Net loss								(7,225)		(7,225)
Balance at Mar. 31, 2024					$ 1	92,212	11	(106,797)		(14,573)
Balance, shares at Mar. 31, 2024					6,469,115
Balance at Dec. 31, 2023					$ 1	91,383	(47)	(99,572)		(8,235)
Balance, shares at Dec. 31, 2023					3,552,223,000
Issuance of common stock in lieu of cash for SEPA commitment fee										81
Net loss										(18,061)
Convertible Note conversion into common stock, shares					441,696
Balance at Sep. 30, 2024					$ 1	107,408	(74)	(117,618)	485	(9,798)
Balance, shares at Sep. 30, 2024					9,310,522
Balance at Mar. 31, 2024					$ 1	92,212	11	(106,797)		(14,573)
Balance, shares at Mar. 31, 2024					6,469,115
Stock-based compensation						751				751
Foreign currency translation adjustments							(38)			(38)
Net loss								(5,767)		(5,767)
Issuance of common shares and pre-funded warrants through April Public Offering, net of financing costs						4,822				4,822
Issuance of common shares and pre-funded warrants through April Public Offering, net of financing costs, shares					1,323,250
Issuance of common stock per Convertible Note conversion						1,028				1,028
Convertible Note conversion into common stock, shares					256,886
Issuance of common shares through May Inducement Offer, net of financing costs						1,818				1,818
Issuance of common shares through May Inducement Offer, net of financing costs, shares					1,069,800
Exercise of common stock warrants						100				100
Exercise of common stock warrants, shares					50,000
Exercise of pre-funded warrants						2				2
Exercise of pre-funded warrants, shares					196,500
Issuance of RSUs for liability settlement						105				105
Balance at Jun. 30, 2024					$ 1	100,838	(27)	(112,564)		(11,752)
Balance, shares at Jun. 30, 2024					3,572,679
Issuance of common stock for legal settlement						150				150
Stock-based compensation						691				691
Foreign currency translation adjustments							(47)			(47)
Net loss								(5,054)	(15)	(5,069)
Issuance of common stock per Convertible Note conversion						211				211
Convertible Note conversion into common stock, shares					184,810
Exercise of common stock warrants						2,736				2,736
Exercise of common stock warrants, shares					1,737,500
Issuance of common stock for liability settlement						282				282
Issuance of common stock for liability settlement, shares					120,847
Issuance of common stock for legal settlement, shares					20,000
Issuance of common stock for Reverse Stock Split fractional shares
Issuance of common stock for Reverse Stock Split fractional shares, shares					79,438
Issuance of common shares and warrants per subscription agreement						1,000				1,000
Issuance of common shares and warrants per subscription agreement, shares					698,812
Investment in Nova Cell						1,500			500	2,000
Balance at Sep. 30, 2024					$ 1	$ 107,408	$ (74)	$ (117,618)	$ 485	$ (9,798)
Balance, shares at Sep. 30, 2024					9,310,522

[1] Retroactively restated for reverse recapitalization.